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Chronic wounds are a major complication in patients with cardiovascular diseases. Cell
therapies have shown potential to stimulate wound healing, but clinical trials using adult
stem cells have been tempered by limited numbers of cells and invasive procurement pro-
cedures. Induced pluripotent stem cells (iPSCs) have several advantages of other cell types,
for example they can be generated in abundance from patients’ somatic cells (autologous)
or those from a matched donor. iPSCs can be efficiently differentiated to functional en-
dothelial cells (iPSC-ECs). Here, we used a murine excisional wound model to test the
pro-angiogenic properties of iPSC-ECs in wound healing. Two full-thickness wounds were
made on the dorsum of NOD-SCID mice and splinted. iPSC-ECs (5 × 105) were topically
applied to one wound, with the other serving as a control. Treatment with iPSC-ECs signifi-
cantly increased wound perfusion and accelerated wound closure. Expression of endothelial
cell (EC) surface marker, platelet endothelial cell adhesion molecule (PECAM-1) (CD31), and
pro-angiogenic EC receptor, Tie1, mRNA was up-regulated in iPSC-EC treated wounds at
7 days post-wounding. Histological analysis of wound sections showed increased capil-
lary density in iPSC-EC wounds at days 7 and 14 post-wounding, and increased collagen
content at day 14. Anti-GFP fluorescence confirmed presence of iPSC-ECs in the wounds.
Bioluminescent imaging (BLI) showed progressive decline of iPSC-ECs over time, suggest-
ing that iPSC-ECs are acting primarily through short-term paracrine effects. These results
highlight the pro-regenerative effects of iPSC-ECs and demonstrate that they are a promis-
ing potential therapy for intractable wounds.
Introduction
Due to poor circulation and prolonged tissue ischaemia, many patients with peripheral arterial disease
(PAD) develop chronic wounds or ulcers on their lower limbs, which can become infected and often ne-
cessitate amputation of the affected foot or leg. The complications associated with infection and amputa-
tion also lead to increased mortality in these patients, particularly in diabetics. Revascularization therapies
improve wound healing in patients with critical limb ischaemia, yet chronic wounds remain a major indi-
vidual and societal burden, with estimated global cost of care in excess of US$ 22 billion each year [1,2].
Current treatments for chronic wounds are largely focused on cleaning, infection control and debride-
ment of dead tissue. The gold-standard in chronic wound care is the split-thickness autograft, which is a
patch of skin taken from a healthy region and grafted on to the wound [3]. Other treatment options in-
clude bioactive dressings and donor keratinocytes, but these have limitations and additional therapies are
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required to better address the microvascular deficiency, which underlies the development of these wounds and con-
tributes to their persistence and re-occurrence.
Acute wound healing comprises four overlapping stages; haemostasis, inflammation, proliferation and remodelling
[4]. The inflammation and cellular proliferation phases take place from hours to several weeks after an injury and
involve the recruitment of inflammatory cells to the wound site, formation of extracellular matrix (ECM) proteins
and granulation tissue, keratinocyte migration, contraction and wound closure. Angiogenesis, the growth of new
blood vessel networks, is a vital component of these processes and is dependent upon pro-angiogenic growth factors
released by supporting cells, proliferation and migration of local endothelial cells into the wound bed, and recruitment
of bone marrow-derived stem cells/endothelial progenitor cells (EPCs) [4-7]. The pathophysiology of chronic wounds
is complex and disordered, but can be largely attributed to persistent inflammation and a lack of adequate tissue
perfusion in the region, exacerbated by failure of ischaemia-mediated angiogenesis in the wound. Collagen deposition
is also reduced in diabetic/PAD patient wounds and the collagen that is present is often glycated, which impairs the
adherence of new keratinocytes to the ECM [8]. Inflammation is also known to be the primary driving force behind
excessive scar formation when a wound does eventually heal [9]. Meanwhile, the inability of EPCs and supporting
cells to form new blood vessel networks to clear necrotic debris and deliver oxygen and nutrients to the granulation
tissue maintains the wound’s inflammatory status. Therapies that can effectively resolve either or both pathological
processes are key to breaking the vicious cycle of failed healing in chronic wounds.
Stem cell therapy is a promising strategy to enhance angiogenesis and promote healing of chronic wounds. Adult
stem and progenitor cells have been studied extensively in animal models of wound healing and appear to exert
their beneficial effects via multiple mechanisms, including recruitment of other cells types, such as keratinocytes,
macrophages and EPCs [10-12]. They have also been shown to produce collagen types I and III, which are critical
for regeneration of the ECM and are the source of structural integrity and tensile strength in the healing tissue [13].
Clinical trials with bone marrow-derived stem cells are underway and there are a handful of published studies in both
acute (surgical) and chronic (venous insufficiency and diabetic) wounds, which have reported consistent decreases
in wound size, particularly with repeat treatments [14-17]. EPCs and embryonic stem cell derived endothelial cells
have also been tested in animal models and improve wound healing via increased vascularization [18,19]. Indeed, a
common beneficial feature of all stem cell therapies seems to be their pro-angiogenic effect.
Induced pluripotent stem cells (iPSCs) are derived by reprogramming somatic cells, such as dermal fibroblasts.
They have unlimited self-renewal capacity and are therefore an abundant potential source of autologous or donor
matched cells for therapy and may be more clinically translatable than other stem cell types. iPSCs can be differen-
tiated to functional endothelial cells (iPSC-ECs) with high efficiency and reproducibility. We have shown previously
that iPSC-ECs enhance angiogenesis and improve perfusion recovery in a mouse model of peripheral arterial disease
[20,21]. The objective of the current study was to determine whether the pro-angiogenic properties of iPSC-ECs can
be harnessed to promote wound healing. We demonstrate for the first time that iPSC-ECs enhance wound angiogen-
esis and perfusion, promote physiological collagen deposition and accelerate wound closure in a murine excisional
wound healing model. These findings suggest that iPSC-ECs have potential as a treatment for chronic wounds and
support further development of clinical grade iPSC-ECs for therapeutic angiogenesis.
Methods
iPSC reprogramming and differentiation to iPSC-ECs
Human iPSCs were generated via retroviral overexpression of Oct4, Klf4, Sox2, and c-Myc (OKSM) transcription
factors in human dermal fibroblasts derived from healthy subjects. The iPSCs were differentiated to endothelial cells
using previously described methods [20-23] (Supplementary Figure S1). The cells were transduced with a double
fusion reporter construct encoding GFP and firefly luciferase, to enable in vivo fluorescence and bioluminescent
imaging (BLI).
Wound healing procedure
The wounding procedure was adapted from that previously described by Galiano et al. [24] and Dunn et al. [25]. Male
NOD/SCID mice were used at 8–10 weeks of age. The operative region of the mouse’s back was prepared by removing
the fur with clippers and a light depilatory cream, and two wound outlines were made, using a sterilized 5-mm biopsy
punch. The skin in the middle of the outline was lifted using serrated forceps and full-thickness wounds were cut and
excised using iris scissors. Silicone splints (approximately 10 mm diameter) were used to prevent wound closure via
contraction. An adhesive was applied sparingly to one side of the splint and the splints were centred over the wounds.
The splints were then secured in place using interrupted 6-0 PROLENETM sutures (8805H, Ethicon LLC, San Lorenzo,
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Puerto Rico). After splinting, the mice were scanned with a laser Doppler (MOOR-LMD V192, Moor Instruments,
U.K.) for wound perfusion measurement. They were placed on a heat mat in the prone position and the wound area
was scanned three times per mouse per time point. Doppler scans were performed on alternate days post-wounding,
up to and including day 14. Subsequent to the initial Doppler scan, cell treatments (5 × 105 iPSC-ECs suspended
in vehicle containing a 1:1 ratio of endothelial basal medium to growth factor reduced Matrigel) were injected into
the wounds and the wounds were covered with adhesive OpsiteTM dressings (66000041, Smith & Nephew, London,
U.K.). All wound healing experiments and associated procedures were conducted in accordance with National Health
and Medical Research Council (NHMRC) guidelines for the care and use of animals for scientific purposes and were
approved by the Sydney Local Health District Animal Welfare Committee, Protocol #2014-004A.
BLI
BLI was used for longitudinal tracking of iPSC-EC survival in vivo and was performed with an IVIS Lumina XRMS
and Living Image software (version 4.5, PerkinElmer, Waltham, MA 02451, U.S.A.). The mice were anaesthetized
with 2% isoflurane and d-luciferin (100 μl, 375 mg/kg) was administered by subcutaneous injection in a medial
position immediately inferior to the wound sites. Bioluminescence intensity was calculated as the maximum mean
radiance (photons/second/cm2/steradian) recorded in pre-defined ROI centred over the wounds. BLI was performed
on alternate days post-wounding, up to and including day 14.
Histological analysis of explanted wounds
Wound explants were fixed in 4% paraformaldehyde for up to 4 h at room temperature, then changed to 70% ethanol
for at least 24 h. Paraffin infiltration was performed overnight by an automated tissue processor (Leica TP1020, Leica
Biosystems Nussloch GmbH, Heidelberger Straße 17-19 69226 Nussloch, Germany). The infiltrated samples were
then embedded in paraffin blocks for sectioning. Tissue samples were cut into 5-μm thick transverse sections us-
ing a rotary microtome, deparaffinized, and stained. Milligan’s Trichrome stain was performed to visualize colla-
gen content. For immunohistochemistry analysis, paraffin sections were stained using immunohistochemistry tech-
niques with primary antibodies anti-CD31 (Abcam, U.S.A.) for endothelial cells and anti-CD68 (Abcam, U.S.A.)
for macrophages. Fluorescence microscopy was then used to visualize cell markers using Alexa Fluor 594 conjugated
secondary antibodies. Anti-GFP staining was done using cryosectioning. Briefly, tissue was fixed in 4% paraformalde-
hyde for up to 4 h at room temperature then changed to 30% sucrose for at least 24 h. Tissue was then fixed in op-
timum cutting temperature (OCT) compound and kept at −80◦C until cryosectioning. Samples were sectioned into
40-μm thick transverse sections and dropped into PBS in order for the residual O.C.T. to dissolve. Sections were then
stained using standard free-floating techniques with a FITC-conjugated anti-GFP antibody (GeneTex). Both paraffin
and cyrosections were then mounted and coverslipped with DAPI-containing mounting media (Vectashield, Vector
Laboratories Inc., CA, U.S.A.).
Analysis of host angiogenic gene expression in wounds
Total RNA was isolated from explanted control and iPSC-EC treated wounds with TRIzol reagent. Real-time quanti-
tative PCR analysis was performed to evaluate the expression of murine vascular endothelial cadherin (VE-cadherin;
sense: 5′-TCCTCTGCATCCTCACTATCACA-3′, antisense: 5′-GTAAGTGACCAACTGCTCGTGAAT-3′) ,
vascular endothelial growth factor receptor-1 (Flt-1; sense: 5′-GAGGAGGATGAGGGTGTCTATAGGT-3′,
antisense: 5′- GTGATCAGCTCCAGGTTTGACTT-3′), vascular endothelial growth factor receptor-2 (KDR;
sense 5′-CCCTGCTGTGGTCTCACTAC-3′, antisense: 5′-CAAAGCATTGCCCATTCGAT-3′), platelet en-
dothelial cell adhesion molecule (PECAM-1; sense: 5′-GAGCCCAATCACGTTTCAGTTT-3′, antisense:
5′-TCCTTCCTGCTTCTTGCTAGCT-3′), tyrosine kinase with Ig-like and EGF-like domains-1 (Tie-1; sense: 5′-
CAAGGTCACACACACGGTGAA-3′, antisense: 5′-GCCAGTCTAGGGTATTGAAGTAGGA-3′), and vascular en-
dothelial growth factor (VEGF; sense: 5′-TGCCAAGTGGTCCCAG-3′, antisense: 5′-GTGAGGTCTTGATCCG-3′).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sense: 5′-GGGGCTCTCTGCTCCTCCCTGT-3′, antisense:
5′-CGGCCAAATCCGTTCACACCGA-3′) was used as a loading control. Relative gene expression was calculated as
fold change compared with paired control wounds.
Quantificative analysis of bioluminescence and histological images
Quantification of bioluminescence images was performed using LivingImage 4.5 (PerkinElmer) software. Histolog-
ical and immunohistochemical sections were imaged using a Zeiss Upright Olympus fluorescence multichannel mi-
croscope, captured with a Nikon DP Controller 2.2 (Olympus, Japan). Immunohistochemical and histopathological
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Figure 1. iPSC-EC engraftment in wounds
iIPSC-ECs were transduced with a double fusion reporter construct encoding GFP for fluorescence imaging and firefly luciferase
for BLI. (A) Representative IVIS images, showing bioluminescent signal present in iPSC-EC-treated wounds (right) on days 0, 6 and
14 post-wounding. (B) Declining bioluminescent signal in wounds over time, relative to control wound background signal. (C) GFP
staining (green) with DAPI nuclear stain (blue) in control and iPSC-EC treated wounds at on days 7 and 14 post-wounding (n=6 per
treatment group).
analyses were done using ImageJ. Briefly, regions of interest (ROIs) were drawn around the wound site. For endothe-
lial cells and fibroblasts, positive staining was quantified as individual particles counted based on a common threshold
intensity. All cell types were quantified from n=6 sections per group per time point.
Statistics
Data are expressed as mean +− S.E.M. and indicated in figures as *P<0.05, **P<0.01. The data were compared using
paired Student’s t tests followed by Bonferoni’s post-hoc test using GraphPad Prism version 5.00 (GraphPad Software,
San Diego, CA) for PC. IPSC-EC experimental samples were paired to control wounds within the same mouse.
Results
Engraftment of iPSC-ECs within wounds decreases following
transplantation
BLI was used to quantify the levels of iPSC-EC engraftment within wounds over time. Transfection of iPSC-ECs
with a dual-report construct containing both the enhanced GFP (eGFP) and the firefly luciferase enzyme enabled
visualization and quantification of transplanted iPSC-ECs. Intramuscular injection of d-luciferin substrate catalysed
a bioluminescent reaction through the firefly luciferase enzyme within viable iPSC-ECs that could be visualized and
quantified using the IVIS apparatus (Figure 1A). Bioluminescence quantification over 14 days showed that iPSC-EC
presence in wounds decreases steadily over time (Day 0: 1.39 × 107 +− 5.61 × 106 compared with Day 14: 4.04 ×
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Figure 2. iPSC-EC treatment increases expression of pro-angiogenic genes
qPCR analysis of wound mRNA revealed a significant up-regulation of PECAM (CD31) and endothelial cell receptor, Tie-1, ex-
pression in iPSC-EC wounds on day 7 post-wounding. This was resolved by day 14. No significant differences in endothelial cell
surface marker VE-cadherin (CD144), VEGF, VEGF receptor 1 (Flt1) or VEGF receptor 2 (KDR) expression were measured (*P<0.05
compared with controls, n=6 per treatment group).
104 +− 1.53 × 104 photons/cm2/s/steradian). The largest decrease in bioluminescence occurred between days 2 and
4 (Day 2: 8.36 × 106 +− 5.44 × 106 compared with Day 4: 7.66 × 105 +− 3.65 × 105 photons/cm2/s/steradian, Figure
1B). Immunohistochemistry staining of the eGFP marker identified iPSC-ECs engrafted within the wound site at day
7, and a smaller proportion remaining at 14 days post-transplantation (Figure 1C).
Engraftment of iPSC-ECs correlates with up-regulation of host
angiogenic gene expression
Functional angiogenesis is a complex process regulated by numerous cells types and growth factors. Ischaemic/injured
tissues undergoing revascularization processes are often identified by the up-regulation of key angiogenic genes in-
cluding VE-cadherin, VEGF, Flt-1, KDR, PECAM, and Tie-1. Wounds were explanted at days 7 and 14 for qPCR
analysis to determine levels of these classical angiogenic genes. Increasing trends were observed in the expression of
VE-cadherin, Flt-1, and KDR in iPSC-EC treated wounds when compared with control wounds at both time points,
however no statistical significance was obtained. At day 7, PECAM and Tie-1 genes were found to be significantly
u-regulated by 350 +− 89 and 534 +− 134% in iPSC-EC treated wounds compared with control wounds (Figure 2).
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Figure 3. iPSC-EC treatment increases vascular density and wound perfusion
(A) Representative laser Doppler images, showing perfusion in control and iPSC-EC treated wounds on days 0, 4, 8 and 18 post–
wounding. (B) Wound perfusion in iPSC-EC treated wounds, relative to their respective control wounds. Increased perfusion in
iPSC-EC treated wounds was most pronounced during the first week of healing. (C) Representative photomicrographs of wounds,
showing increased neo-vessel formation in iPSC-EC wounds relative to controls. (D) Capillary density, as measured by CD31+
staining, was significantly increased in iPSC-EC wounds at both early and late time points (*P<0.05, n=6 per treatment group).
At day 14, VEGF expression was significantly up-regulated by 12 +− 4% in iPSC-EC treated wounds compared with
controls (Figure 2).
Wounds treated with iPSC-ECs exhibit increased angiogenesis
The anatomical hallmarks of angiogenesis include increased blood perfusion and high density of neo-capillary forma-
tion. Non-invasive IR laser Doppler imaging was conducted at the wound sites over 14 days to visualize and quantify
levels of blood perfusion for the duration of wound healing (Figure 3A). Laser Doppler analysis revealed a maximum
of two-fold increase in wound perfusion compared with control within the first 4 days following treatment in iPSC-EC
treated wounds compared with control (Figure 3B). This gradually decreased back to baseline control wound perfu-
sion levels by day 10. The subcutaneous layers of iPSC-EC treated, and control wounds were photographed following
explant. A higher density of observable blood vessels was observed in iPSC-EC treated wounds compared with con-
trol (Figure 3C). To assess neo-capillary formation, cross-sections of wound explants were stained using the CD31
endothelial cell marker. At day 7, iPSC-EC treated wounds showed a 16-fold increase in capillary density compared
with control wounds, which decreased to a four-fold increase by day 14 (Figure 3D).
iPSC-EC treatment enhances the native wound healing process
Native wound healing processes involve numerous cell phenotypes responsible for rebuilding the tissue architecture
necessary for cell repopulation. Of these cell types, fibroblasts are largely implicated as essential matrix remodelling
cells which facilitate neo-collagen deposition as a temporary matrix for cell growth and tissue regeneration. Using
trichrome staining, wound cross-sections were quantified for levels of collagen deposition. iPSC-EC treated wounds
showed a 20 +− 4% increase in collagen deposition at day 14 compared with control wounds (Figure 4B). Similar
trends were observed with macrophage infiltration. At day 14, iPSC-EC treated wounds showed a 174 +− 6% increase
in macrophage numbers compared with control wounds (Figure 5). The functional outcomes of wound healing were
measured by taking three diameter measurements of wounds over 14 days and represented as percentage of total
wound closure. iPSC-EC treated wounds show accelerated wound closure from day 2, which was significant on days
4 and 10 post-wounding and achieved complete wound closure 4 days earlier than control wounds (Figure 4A).
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Figure 4. iPSC-EC treatment increases collagen deposition and accelerates wound closure
(A) Representative photomicrographs, showing progressive wound closure over a 14-day period. Rate of closure was significantly
increased in iPSC-EC treated wounds compared with controls. (B) Milligan’s Trichrome staining for collagen content. No differences
were observed on day 7; by day 14 iPSC-EC treated wounds had significantly higher collagen content (*P<0.05, **P<0.01, n=6
per treatment group).
Figure 5. iPSC-EC treatment increases macrophage infiltration
(A) Anti-CD68 staining for macrophage infiltration. No differences were observed on day 7; by day 14 iPSC-EC treated wounds had
significantly macrophage infiltration (*P<0.05, n=6 per treatment group).
Discussion
Chronic wounds and ulcers persist in a state of pathological inflammation, characterized by increased proteolytic ac-
tivity, increased production of reactive oxygen species (ROS), senescent or dysfunctional fibroblasts, neutrophils and
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macrophages, and reduced pro-angiogenic growth factors and cytokines [4,7]. The aetiology of chronic wound for-
mation in diabetes and peripheral arterial disease is multifactorial, but a major cause is underlying vasculopathy and
diminished angiogenesis. The angiogenic response to ischaemia declines naturally with age and is further impaired in
patients with vascular disease, who have reduced number and functionality of circulating EPCs [26-30]. The impor-
tance of angiogenesis in wound healing has been highlighted by interventional studies, which have shown that topical
application of pro-angiogenic factors, such as VEGF or bFGF, is beneficial in accelerating diabetic wound healing in
mice, while neutralizing them has the opposite effect [31-33]. However, clinical trials using single growth factors to
boost angiogenesis have been largely unsuccessful, which likely reflects the complex regulation of angiogenesis in
vivo and the need for a multifactorial approach [34].
Bone marrow and adipose tissue derived MSCs and EPCs have been in development for therapeutic angiogene-
sis for the past two decades, and have shown promise in promoting wound healing , however limited availability of
healthy adult stem cells, and invasive aspiration procedures have tempered their use. iPSCs and their derivatives have
several advantages, such as their relatively abundant supply, their non-controversial origins and the lack of immuno-
genicity if used for autologous transplantation [35]. Furthermore, the development of iPSC banking, the creation
of multiple iPSC lines representing commonly present HLA allele combinations, means that patients could receive
non-autologous cells without evoking an immune rejection, increasing the throughput while simultaneously reducing
the time, cost and invasiveness of pluripotent cell therapies [36].
Here, we demonstrate the pro-angiogenic and wound healing capabilities of iPSC-ECs in a murine excisional
wound model. Angiogenesis is vital for the formation and maintenance of granulation tissue in the first 2–4 days
post-wounding. Neo-vessel formation typically begins around this time, peaking around day 7 before giving way to
remodelling and maturation of the newly formed vasculature. We observed significantly accelerated wound closure
in iPSC-EC treated wounds, as well as increased wound perfusion in the first week of healing, which was associated
with a significant increase in endothelial cell surface marker PECAM-1 (CD31) staining in the wounds at both 7 and
14 days post-wounding. Consistent with previously described temporal patterns of angiogenesis in wound healing,
absolute laser Doppler perfusion measurements decreased in both groups during the second week, approaching those
of the surrounding healthy skin, as new dermis progressively covered exposed capillaries at the wound surface. Ex-
pression of PECAM-1 and Tie-1 mRNA was significantly up-regulated in iPSC-EC wounds on day 7 but was similar
to expression in control wounds by day 14. Tie 1 is an endothelial cell specific orphan receptor, which has been shown
to promote sprouting angiogenesis via regulation of Tie 2 receptor signalling [37].
iPSC-EC treatment also increased wound collagen deposition; sections from wounds treated with iPSC-ECs had
significantly higher collagen content than the control wounds on day 14. Collagen deposition is vital for healthy
wound healing, but the implication of increased collagen depends on the stage of healing as well as the types of colla-
gen present; in the proliferative stage of healing collagen provides a matrix to support inflammatory and vascular cells
as well as forming a stronger barrier than the fibrin clot [38]. In the late stages (remodelling), a reduction in collagen
content is desirable to limit scarring. Collagen deposition begins within the first 24 h after wounding and peaks be-
tween 1 and 3 weeks later, depending on the wound site and size. As these wounds were still actively healing and in the
proliferative phase at day 14, the observation of increased collagen is most likely indicative of a more advanced stage of
healing compared with the controls, rather than excessive scarring. We also observed increased macrophage infiltra-
tion in iPSC-EC treated wounds at day 14 post-wounding, as evidenced by significantly increased CD68+ staining. In
normal wound healing, macrophage infiltration peaks during the inflammatory phase (day 1–3 post-wounding) be-
fore subsiding. We observed no difference in CD68+ staining between control and iPSC-EC treated wounds at 7 days
post-wounding. However, by day 14 iPSC-EC treated wounds had significantly greater CD68+ staining compared
with their respective controls, suggesting sustained macrophage activity. This observation may be due to increased
recruitment of macrophages in response to iPSC-ECs.
Poor cell survival and engraftment remains a major limitation to the long-term efficacy of cell therapies and there-
fore their suitability for clinical use. Most cells are lost within the first 48 h after administration, due to poor retention
and cell death due to excessive inflammation, ischaemia or anoikis, the programmed death that occurs in endothelial
cells and other anchorage-dependent cell types when they lose their interaction with ECM [39]. Very few previous
wound healing studies included longitudinal tracking of the implanted cells to determine their eventual fate and those
that did reported low rates of engraftment [40,41]. We used a firefly luciferase reporter gene construct and BLI for lon-
gitudinal tracking of iPSC-EC survival in vivo and although iPSC-EC fluorescent and bioluminescent signal was still
detectable in the wounds 14 days post-treatment, we observed a substantial and progressive decline over the 2-week
period. These data are consistent with previous in vivo survival of iPSC-ECs and suggest that the pro-angiogenic and
pro-healing effects of our cells were primarily mediated via secretion of paracrine factors rather than engraftment or
proliferation of the cells themselves [42]. Despite low rates of engraftment, stem cell treatments consistently evoke a
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beneficial response. This suggests that even small increases in retention could translate to sizeable improvements in
tissue regeneration and long-term recovery and we are conducting further studies seeding iPSC-ECs on biomaterial
scaffolds to determine if this can increase their in vivo longevity and potentiate their beneficial effects.
Limitations
NOD/SCID mice are widely used in human haematopoietic cell studies and are an ideal strain for human cell trans-
plantation because they lack functional B and T lymphocytes, lack the ability to mount an antibody-mediated response
and additional deficiencies in their innate immune system allow for increased donor cell engraftment [43]. However,
the blunted immune response to the cells creates a somewhat artificial environment in comparison with the situation
in an immune competent organism. That being said, it is not possible to conduct pre-clinical, mechanistic investi-
gations using human cells in other species without modulating the immune response. It is anticipated that the use
of autologous or donor matched cells clinically would also mitigate the effects of immune rejection of the engrafted
cells by the recipient, therefore we considered the NOD/SCID mouse to be the most suitable and appropriate model
for these studies. It should also be noted that these mice are neither aged nor diabetic, so most innate wound healing
capabilities are intact. This means that treatment effects are more difficult to detect, thus we anticipate an even more
pronounced improvement after iPSC-EC treatment if we were able to use these cells in such a model.
Finally, we acknowledge that the iPSC-ECs used in the present study were differentiated from iPSCs that were
generated using integrating viral vectors. These cells may not be suitable for use in a clinical setting because of the
possibility of foreign DNA integrating into the host genome. However, the development of reprogramming protocols
using small molecules means that iPSC-ECs for clinical applications can be generated without the use of viral vectors.
Conclusion
In the present study, we have demonstrated for the first time that human iPSC-ECs have pro-angiogenic functionality
in wound healing, promote fibroblast infiltration and collagen deposition and accelerate wound closure. Longitudinal
tracking of iPSC-ECs in vivo revealed a progressive decline in surviving iPSC-ECs over time, indicating that the cells
are acting primarily through short-term paracrine effects. These findings have provoked further studies optimising
iPSC-EC delivery to improve in vivo survival and engraftment rates, and also make a strong case for the development
of clinical grade iPSCs and their derivatives for therapeutic angiogenesis in patients with vascular diseases.
Perspectives
(i) Ischaemia-mediated angiogenesis is impaired in patients with cardiovascular disease and diabetes,
which leads to the development of intractable wounds and ulcers.
(ii) Here, we show that human iPSC-derived endothelial cells (iPSC-ECs) promote angiogenesis, in-
crease collagen deposition and accelerate healing in a murine wound healing model.
(iii) Further development of human iPSC-ECs for therapeutic angiogenesis is a promising strategy to
reduce the burden of chronic wounds in patients with peripheral arterial disease and diabetes.
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